Caveolin (cav-1) and the GPI-anchored a-folate receptor (aFR) are membrane proteins both found associated to caveolar structures. Several studies in tumor cells independently reported cav-1 downregulation and aFR overexpression. Here we analysed the expression of the two molecules in normal and tumor ovarian samples derived from fresh specimens and from cultured cell lines. Whereas normal ovary surface epithelial cells displayed only cav-1 expression, ovarian tumor surgical samples and cell lines (COR, IGROV1, OVCAR3 and OVCA432) displayed high aFR and low-level or no cav-1 expression, except those cell lines (SKOV3 and SW626) with the lower aFR expression. SKOV3, but not two aFR-negative non-ovarian cell lines, exhibited downregulation of cav-1 expression following stable aFR cDNA transfection. Conversely, cav-1 transfection in IGROV1 cells led to downregulated aFR expression, together with formation of caveolar structures and reduction of growth capability. Moreover, cav-1 expression was induced in IGROV1 cells by transfection with intracellular anti-aFR antibodies to downmodulate aFR expression. In cav-1 transfected cells, transcriptional activity of the aFR-speci®c promoter P1 was reduced by 70% and an additional speci®c DNA-protein complex was identi®ed by gel-shift assay, indicating that cav-1 expression in¯uences aFR gene transcription. Together these results support the notion that aFR and cav-1 protein expression is reciprocally regulated in ovary cancer cells.
Introduction
Caveolae are specialized membrane invaginations, and the 22 ± 24 kDa integral membrane protein caveolin, is the major structural and functional component . Following the cloning of three dierent but closely related genes, caveolin has been termed caveolin-1 (cav-1) . Cav-1 and cav-2 are widely expressed on endothelial cells and ®broblasts, whereas cav-3 expression is muscle-speci®c (Tang et al., 1996; Scherer et al., 1997) . Cav-1 is anchored to the cell membrane by a typical hairpin structure with both N-terminal and C-terminal domains facing the cytoplasm. This structure allows interaction of cav-1 proteins with each other and with cav-2 proteins, leading to formation of homo-and hetero-oligomers, which form caveolar macromolecular complexes with cholesterol and glycosphingolipids (Scherer et al., 1997; Murata et al., 1995) .
Several cytoplasmic molecules that participate in signaling events (src-family tyrosine kinases, a-subunits of heterotrimeric G-proteins, Ha-Ras, eNOS) and some receptor tyrosine kinases (EGF receptor, PDGF and insulin receptor) were found to be associated and to co-purify with cav-1 (see : Anderson, 1998; Okamoto et al., 1998 for review) . Interaction between cav-1 and signaling proteins occurs in a region proximal to the N-terminal domain (amino acids 82 ± 101) termed the caveolin scaolding domain (Couet et al., 1997a) . Since caveolin-associated proteins are preferentially bound in their inactive form, their caveolar localization might provide a general mechanism for sequestration and negative regulation of their activity (Couet et al., 1997b; Li et al., 1996) .
The a-folate receptor (aFR) is a 38 kDa glycosylated, GPI-anchored protein that was found in association with caveolar structures on MA104 cells (monkey kidney epithelium), where it was thought to provide a high-anity route for folate internalization through a mechanism called potocytosis . We found that aFR is constitutively expressed at high levels by ovarian carcinoma cells in vivo and in vitro (Miotti et al., 1987) and, in these cells (Alberti et al., 1990; Coney et al., 1991) , aFR is only partially responsible for folate internalization . Antony, (1996) proposed that aFR might aect cell proliferation independently of its involvement in folate internalization. Our own studies in a nude mouse model have shown that aFR expression confers a growth advantage to aFR-transfected cells, and that aFR expression levels in ovarian carcinoma patients correlate with tumor progression (Bottero et al., 1993; Tooli et al., 1997) . Recently, we demonstrated the localization of aFR in IGROV1 ovary carcinoma cells to low-density microdomains, essentially lacking cav-1, in association with heterotrimeric G proteins and the src-like kinase p53-56 lyn (Miotti et al., 2000) .
In the present study we analysed the relationship between cav-1 and aFR expression in normal vs tumoral ovarian surgical specimens and cell lines.
Our data indicate a reciprocal negative regulation between these two molecules.
Results

Cav-1 and a-FR expression on normal and tumor ovary cells
Sections derived from two samples of normal ovary were tested for reactivity with an anti-cav-1 polyclonal antibody and anti-aFR MAb MOv19. Surface epithelial cells revealed basal, polarized staining for cav-1 (Figure 1c ) whereas no staining with MOv19 was detected (Figure 1b) . By contrast, serial sections derived from specimens of eight dierent non-mucinous ovary epithelial tumors revealed intense diuse staining of tumor cells with MAb MOv19 (Figure 1e ,h) but only faint or no reactivity of epithelial tumor cells and mild reactivity of stromal cells using the anti-cav-1 antibody ( Figure 1f ,i respectively).
Expression of cav-1 and aFR was analysed at both the mRNA and protein levels in two short-term cultured normal ovary surface epithelial (OSE) cells, in six ovarian carcinoma cell lines (COR, OVCAR3, IGROV1, OVCA432, SKOV3, SW626) and in A431 cells, an epidermoid vulvar carcinoma cell line known to express cav-1 protein (Couet et al., 1997b) . Western analysis of lysates (Figure 2 ) derived from these cell lines, revealed that ovary cancer cells expressing high aFR levels (COR, OVCAR3, IGROV1, OVCA432) expressed relatively low levels of cav-1 protein ( Figure  2a , lanes 1 ± 4), whereas cell lines displaying low aFR levels (SKOV3 and SW626; Figure 2a , lanes 5 and 6) or no detectable aFR protein expression (A431 cells, Figure 2a , lane 7; OSE1 and OSE2 cells, Figure 2b , lanes 8 and 9), expressed cav-1 protein. Analysis of these cell lines also for the presence of caveolin 2 (cav-2) protein revealed the same expression pattern as for cav-1 protein.
Northern analysis (Figure 3a ) indicated variable levels of aFR mRNA transcript (*1.0 kb in size) in ovarian cancer cell lines, whereas no aFR transcript was detected in A431 cells. Hybridization with the cav-1 probe revealed a *3.0 kb transcript that was highly expressed in A431 cells and in the SKOV3 and SW626 ovary cancer cell lines; only trace amounts or no cav-1 transcripts were detected in the other four cell lines (lanes 1 ± 4). Interestingly, SKOV3 and SW626 cells expressed the lowest level of aFR transcript among the six ovary cancer cell lines tested, consistent with the Western blot results. Densitometric evaluation of the Figure 1 a-FR and cav-1 expression in normal and tumor ovary tissue. Serial sections derived from normal (a ± c) and two dierent tumor (d ± f and g ± i) ovary surgical specimens were tested by immunohistochemistry with anti-aFR MAb (b, e and h) and anti-cav-1 polyclonal antibodies (c,f,i) and for background reactivity with secondary antibody alone (a,d,g ). Normal ovary surface epithelial cells showed a polarized, basal caveolin staining but no detectable aFR expression. The opposite expression pattern was revealed in tumor tissue Oncogene Co-regulation of aFR and cav-1 expression in ovarian cancer M Bagnoli et al band intensity relative to b-actin mRNA (Figure 3b ) suggested an inverse relationship between the expression of cav-1 and aFR mRNA.
In the OSE1 and OSE2 cell lines, expression of cav-1 and aFR transcript (573 and 774 bp, respectively) was evaluated by RT ± PCR, due to the small amount of total RNA extractable from these short-term cultured cells. SKOV3 cells, which express both aFR and cav-1, were used as a positive control. Whereas the cav-1 transcript was detected in OSE1, OSE2 and SKOV3 cells, only the latter displayed aFR transcription (Figure 3c ).
Effect of aFR transfection on cav-1 expression
To examine the possible inverse relationship between cav-1 and aFR expression in ovary cancer cells, we ®rstly investigated the eects of aFR cDNA transfection in SKOV3 cells, which express low levels of aFR but consistently express cav-1 (see Figures 2 and 3 , lane 5), and in A431 and NIH3T3 cells, which both express cav-1.
Western analysis of cellular lysates derived from mock-and aFR-transfected cells (FRt-SKOV3, FRt-A431 and FRt-NIH3T3, respectively), indicated decreased cav-1 protein expression only in FRt-SKOV3 cells ( Figure 4a , lane 2); no change in cav-1 was detected in the other two aFR-transfected cell lines (Figure 4a , lanes 3 ± 6).
Northern analysis followed by densitometry revealed an increase in aFR mRNA levels in FRt-SKOV3 cells (Figure 4b, lane 2) , which was associated with a 51.7%+4.6 reduction in cav-1 mRNA transcript levels ( Figure 4c ) as compared to control mock-transfected cells. In FRt-NIH3T3 cells (Figure 4b , lane 4), aFR neo-expression was associated with only a slight increase in cav-1 mRNA expression (16%+10.2, Figure 4c ) and in FRt-A431 cells (Figure 4b , lane 6), cav-1 mRNA levels remained unchanged, as compared to control cells (Figure 4b , lanes 3 and 5 respectively).
Effect of Cav-1 transfection on IGROV1 cells morphology and growth IGROV1 cells, which display high aFR and very low cav-1 expression, were transfected with the human fulllength cav-1 cDNA, and two of ®ve positive stable clones (IGt-C3, IGt-C52) were studied further. Two of 10 stable clones derived from mock-transfected cells (IGt-M45, IGt-M87) were also analysed.
Electron microscopy revealed no caveolae-like structures in the IGt-M87 (control) clone (Figure 5a ), whereas the transfected IGt-C3 clone (Figure 5b ) showed membrane invaginations morphologically resembling caveolar structures, although a striated coat was not always visible. These caveolar structures were identi®ed not only by their typical¯ask shape, size (90 nm) and location on the cytoplasmic side of the cell membrane, but also by immunogold labeling of cav-1, clearly visible close to the inner face of the plasma membrane (Figure 5c,d) . Interestingly, cav-1 labeling of free vesicles (Figure 5d asterisk) was also observed in the cytoplasm. In control IGt-M87 cells, gold particles were totally absent from both the cell membrane and the cytoplasm (data not shown).
In the in vitro proliferation assay (Figure 6a ), IGt-C3 and IGt-C52 cells displayed an earlier growth arrest as compared to mock-transfected cells , that appeared to grow inde®nitely. Moreover, IGt-C3 cells displayed a decreased ability to form foci as compared with IGt-M87 cells ( Figure 6b ); after 15 days of culture, IGt-C3 cells showed about half the number of foci as IGt-M87 cells (51 vs 92, respectively) and a proportionally lower cell number (2.75610 5 vs 3.96610 5 respectively), although cell size was enlarged. IGt-C3 cells also showed a reduced colony-forming ability in soft agar ( Figure 6c ), with smaller cell colonies than those from mock-transfected cells.
Reciprocal effect of aFR and Cav-1 expression
Western blot analysis of cellular extracts derived from mock-and cav-1-transfected IGROV1 cells ( Figure 7a ) indicated a marked reduction of aFR in the cav-1-expressing IGt-C3 and IGt-C52 clones (lanes 3 and 4, respectively). aFR expression in control, mock-transfected cells was comparable to that in parental IGROV1 cells, and cav-1 protein was not detectable (Figure 7a , lanes 1, 2). However, after several months of culture, the IGt-M45 clone spontaneously displayed a decrease in aFR protein in association with the appearance of a low-level cav-1 expression, and these characteristics were stably maintained (data not shown). The IGt-M87 clone remained stable in its expression of the two proteins over time. Northern blot analysis of cav-1-transfected IGROV1 cells revealed a major cav-1 mRNA transcript of about 600 bp in size and from A431 cells (lane 7) with 1.1% b-octyl-glucoside were analysed by Western blot on 10% acrylamide slab gels. To analyse aFR expression only, samples were run in non-reducing conditions. To better visualize the pattern of aFR expression among the ovary cancer cell lines, the same ®lters were exposed for two dierent times (* : longer exposure). (b) Expression of cav-1, cav-2 and aFR (under the same experimental conditions as in (a)) in two dierent short-term cultured normal OSE cell lines Western blot analysis of cell lysates derived from aFR-transfected cell lines to detect cav-2 protein in those cell lines in which cav-1 expression was modi®ed by aFR, indicated no signi®cant change in cav-2 protein level as compared to the corresponding mocktransfected cells (see Figure 4a) . Evaluation of cav-2 expression in IGROV1 cells induced to express cav-1 by transfection or aFR-downmodulation revealed a faint band in IGt-C3, IGt-C52 and DM99 clones (Figure 7a ,b, respectively).
Regulation of aFR expression in cav-1-transfected IGROV1 cells
The activity of the two promoters P1 and P4 in driving aFR transcription in non-ovarian tumor cells has been described (Elwood et al., 1997) .
To determine whether the apparent inverse relationship between aFR and cav-1 expression was aected at the transcriptional level, the ability of the aFR-speci®c P1 and P4 promoter fused to CAT (P1PD-and P4HA-CAT) to drive transcription of the reporter gene was evaluated in cav-1-transfected IGROV1 cells. IGt-C3 cells showed no signi®cant changes in P4HA transcription eciency, whereas a consistent decrease in P1PD transcriptional activity was detected (33.3%+5.5 of control cells, Figure 8a) . A shorter P1 promoter construct lacking the 5'-¯anking region of P1PD, called PCR4 (from +58 to +261 of P1PD, Figure 8a ,b) was also evaluated. Since in IGt-C3 cells the transcriptional activity of P1PD-and PCR4-CAT constructs were almost equally inhibited, we hypothesized this minimal region to be possibly involved in the downmodulation of P1 transcriptional activity in cav-1-expressing cells.
Gel-shift assays with nuclear extracts derived from IGt-C3 and IGt-M87 cells, using two overlapping fragments of about 100 bp derived from PCR4 as probes (fragment A: +58 to +148; fragment B: +131 to +261), revealed a dierent pattern of bands in the two cell lines using probe A, but not with probe B (Figure 8c ). Thus, in IGt-C3 cells, an additional transcriptional factor(s) associates with the aFR-P1 promoter region.
Discussion aFR and cav-1 are distinct proteins, which associate with membrane microdomains characterized by high cholesterol content and detergent insolubility (Simons and Ikonen, 1997) . In this study, we provide evidence for their reciprocal negative regulation in ovary cancer cells and show that cav-1 exerts its inhibition of aFR expression at the transcriptional level.
Loss or reduction of caveolae and of cav-1 expression was ®rst described in NIH3T3 cells transformed by activated oncogenes (Koleske et al., 1995) and more recently, in cell lines derived from breast and lung cancer (Lee et al., 1998; Racine et al., 1999) . Based on several observations, it has been suggested that regulation of cav-1 gene expression might be a critical point in maintaining the transformed phenotype and that cav-1 itself might be considered a tumor suppressor gene (Engelman et al., 1998b; Lee et al., 1998) .
Our analysis of eight dierent specimens of primary non-mucinous ovary cancers revealed little or no cav-1 expression on the tumor cells. All of these tumors reportedly express medium-high levels of aFR (Miotti et al., 1987; Tooli et al., 1997) . Overexpression of aFR has been associated with tumor transformation and progression in experimental models and in ovarian cancer patients (Bottero et al., 1993; Tooli et al., 
. Interestingly, we detected expression of cav-1 but not aFR, at both the mRNA and protein levels in normal ovary surface epithelium (OSE), which is the source of most ovarian carcinomas, as well as in shortterm cultured OSE cells. The analysis of six ovary carcinoma cell lines also indicated the inverse relationship between aFR and cav-1 expression. Moreover, stable transfection of aFR or cav-1 cDNA to enhance expression levels of the respective molecule resulted in downregulation of the other at both the mRNA and protein levels. However, this reciprocal regulation appears to be restricted to cell lines that constitutively express aFR, since aFR transfection aected cav-1 expression only in SKOV3 ovarian carcinoma cells but not in NIH3T3 or A431 cells, which do not normally express the aFR. Finally, intracellular expression of anti-aFR antibodies in IGROV1 cells led to a dramatic decrease in aFR expression and a concomitant increase in cav-1 in these cells, providing a formal proof that the two molecules are inversely regulated. Consistent with previous studies in dierent model systems , we also observed reduced growth rate, alteration of morphology and reduced proliferation in semi-solid medium following stable induction of cav-1 expression in IGROV1 cells, suggesting a partial regression of the transformed phenotype. Since a marked reduction in aFR expression was also evident, it is possible that a balance in the expression of the two molecules represents a critical point in maintaining the transformed phenotype. Thus, analogous to the role of the HerB-2 oncogene in breast cancer cells (Engelman et al., 1998a) , neo-expressed aFR might exert its role in ovarian tumorigenesis by a mechanism involving inhibition of cav-1 expression.
Interestingly, cav-1-transfected IGROV1 cells expressed a 3.0 kb cav-1 mRNA transcript, indicating the induction of endogenous cav-1 gene transcription in these cells. This observation, together with the ®ndings of aFR and cav-1 inverse regulation, indicate that no major modi®cations of the cav-1 gene (e.g., deletion) are associated with cav-1 downmodulation in the ovarian oncotype. Methylation is one mechanism described to be responsible for cav-1 downregulation in breast tumors (Engelman et al., 1999a) ; the putative role of methylation in regulating cav-1 expression awaits analysis in ovary cancer cells.
Cav-1 and cav-2 proteins are co-expressed in some normal tissues (Scherer et al., 1997) and we detected the two proteins in cell lysates derived from normal OSE cell lines. Those ovary cancer cell lines that expressed cav-1 also revealed the presence of cav-2 protein. Whereas cav-1 downmodulation induced by aFR transfection did not correlate with substantial changes in cav-2 expression levels, cav-1 upregulation obtained by transfection with cav-1 cDNA or intracellular anti-aFR scFv, was accompanied by limited cav-2 expression, possibly related to the partial activation of the endogenous cav-1 gene. Although most oncogenic stimuli appear to aect cav-1 expression only, concurrent modulation of cav-2 expression can also occur in some cases (Engelman et al., 1999b) .
The existence of multiple mechanisms regulating cav-1 transcription is now being ascertained. Activation of p42/44 MAP kinase and protein kinase A signaling cascades (Engelman et al., 1999b) , as well as SREBP binding to sterol regulatory element (SRE)-like sequences identi®ed on the cav-1 gene promoter (Bist et al., 1997) , were found to inhibit cav-1 gene transcription in speci®c cell types.
Our results demonstrate that neo-expression of the cav-1 protein in ovary tumors has an inhibitory eect on aFR gene transcription. The activity of two transiently transfected constructs of the P1 promoter (P1PD and PCR4), which is predominantly utilized in ovary cancer cells (Tomassetti et al., manuscript submitted), was dramatically inhibited in IGROV1 cells induced to express the cav-1 protein. Analysis of the shorter P1 promoter construct PCR4, identi®ed the region on which cav-1 expression exerted its negative regulatory eect. No eects on the activity of the P4 promoter, which is the most utilized by nasopharingeal carcinoma cells and lung tissue (Elwood et al., 1997) , were observed. Our ®ndings are consistent with a recent study demonstrating that cav-1 exerts a selective repression on cyclin D1 promoter activity (Hulit et al., 2000) . Moreover, our gel-shift assay indicated an additional DNA-protein complex formed on this P1 promoter region that could account for inhibition of aFR gene transcription in cav-1-transfected IGROV1 cells.
Our data, pointing to the reciprocal negative regulation of the aFR and cav-1 proteins, suggest a new mechanism of cav-1 silencing in ovarian cancer. Our recent ®nding that aFR is functionally associated with the src-kinase p53-56 lyn and the a 1-3 subunit of heterotrimeric G proteins (Miotti et al., 2000) supports the involvement of aFR in intracellular signaling events. Identi®cation of the signaling pathway downstream of aFR, as well as evaluation of the role of three SRE-like sequences found on the aFR P1 promoter (unpublished observation) in controlling aFR gene transcription, will help to clarify the regulatory interplay between aFR and cav-1 in ovarian tumors.
Materials and methods
Cell lines and reagents
Human ovarian carcinoma cell lines COR (Dr G Balconi, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy), OVCAR3 (Dr I Pastan, NIH, Bethesda, MD, USA), IGROV1 (Dr J BeÂ nard, Institute G. Roussy, Villejuif, France), OVCA432 (Dr R Knapp, Dana Farber Institute, Boston, MA, USA), SKOV3 (ATCC, Rockville, MD, USA), SW626 (Memorial Sloan-Kettering Cancer Centre, New York, NY, USA) and the human epidermoid vulval carcinoma cell line A431 (ATCC) were cultured in standard RPMI-1640 medium (2.3 mM folic acid) (Sigma, St. Louis, MO, USA). IGROV1 and SKOV3 cells used for transfection were continuously maintained in folate-de®cient RPMI 1640 medium (SIGMA) (L-IGROV1 and L-SKOV3), as described (Miotti et al., 1995) . Transfected NIH3T3 cells (Bottero et al., 1993) were cultured in standard Dulbecco's modi®ed Eagle's medium (Boehringer-Mannheim, Germany). All media were supplemented with 5 ± 10% fetal calf serum (FCS) and 2 mM L-glutamine (SIGMA).
Short-term cultured normal ovary surface epithelial (OSE) cells were derived from scraping done at the time of surgery for gynecological diseases other than ovarian carcinoma. Cells were cultured in 199-MCDB105 medium (SIGMA) supplemented with 15% FCS and 25 mg/ml gentamicin, as described (Kruk et al., 1990) .
Murine monoclonal antibodies (MAb) MOv18 and MOv19, produced in our laboratory and recognizing two non-competing epitopes of aFR, were puri®ed as described (Miotti et al., 1987 (Miotti et al., , 1995 . Single-chain Fv fragment of MOv19 MAb (Figini et al., 1998) was introduced in a vector containing an endoplasmic reticulum (ER)-retention signal (Persic et al., 1997) to block aFR expression on the cell surface (Figini et al. submitted) .
Rabbit anti-caveolin 1 polyclonal antibody and anticaveolin 2 MAb were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and rabbit anti-b actin was from SIGMA.
Phenylmethylsulfonyl¯uoride (PMSF), 3,3'-diaminobenzidine (DAB) and aprotinin were from SIGMA; lipofectin and geneticin sulfate (G418) from GIBCO BRL (Paisley, Scotland) leupeptin and octyl-b-glucoside from BoehringerMannheim (Germany). 
Immunohistochemistry
Immunohistochemical analysis was performed on serial sections derived from frozen surgical specimens. To avoid non-speci®c binding the samples were preincubated for 20 min with 1% BSA in phosphate-buered saline (PBS). Primary incubation was performed for 30 min at room temperature with anti-aFR MOv19 at 2 mg/ml or rabbit anti-cav-1 diluted 1 mg/ml in PBS and 0.03% BSA (PBS-BSA). PBS-BSA alone was used as negative control. After extensive washing in PBS, samples were incubated for 30 min at room temperature with anti-mouse or anti-rabbit Ig secondary antibody diluted 1 : 200 in PBS-BSA. Endogenous peroxidase activity was inhibited by incubation with a 0.4% solution of H 2 O 2 in PBS for 40 min. Bound antibodies were detected using the avidin-biotin complex method and the Vectastain ABC system (Vector Laboratories, Inc., Burlingame, CA, USA). A 0.1% solution of DAB in PBS was used as a chromogen.
Detergent solubilization and Western blot analysis
Cells grown to con¯uence in a T25¯ask were rinsed twice with PBS and incubated for 1 h at 08C with lysis buer (50 mM Tris-HCl, pH 7.4 plus 0.15 M NaCl, 5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM PMSF, 0.24 U/ml aprotinin, 5 mg/ml leupeptin), containing 1.1% octyl-b-glucoside. Detergent lysates were centrifuged (15 000 g for 15 min at 48C) the supernatant was recovered and protein concentration was determined by BCA protein assay (Pierce, Rockford, IL, USA). Cell lysates were separated on a 10% acrylamide SDS ± PAGE gel and blotted on a nitrocellulose membrane (Hybond C-Super, Amersham). Blots were saturated in Blotto (5% non-fat dry milk, 0.1% Tween in PBS). Filters were incubated with primary antibody diluted in Blotto to 10 mg/ml (MOv18/19) or at the concentration recommended by the manufacturer, followed by the relevant secondary antibodies conjugated with horseradish peroxidase (Amersham) diluted in Blotto. Reactions were developed by ECL (Amersham). To analyse the reactivity of anti-aFR MAbs only, samples were run in non-reducing conditions.
Northern blot analysis and RT ± PCR
Total RNA was extracted using the RNeasy kit (Qiagen, Gmbh, Hilden, Germany) essentially as described by the manufacturer. RNA (15 mg) was run on a 1% agaroseformaldeyde denaturing gel and transferred overnight on a Hybond-N + nylon membrane (Amersham). Full-length cDNAs of cav-1 aFR and human b-actin were labeled with 5'-[a-32 P]dCTP by random priming (Boehringer) and ®lters hybridized with probes (2610 6 c.p.m./ml). The ratio of cav-1 or aFR to human b-actin mRNA was evaluated by densitometry of relevant bands using the Eagle Eye II Image Capture and Software analysis system (Stratagene, La Jolla, CA, USA).
For RT ± PCR assay, total RNA (1 mg) was reversetranscribed using the Gene Amp RNA PCR kit (PerkinElmer Cetus, Norwalk, CT, USA) essentially as suggested by the manufacturer. The following forward (F) and reverse (R) primers were used: aFR: 5'7ATG GCT CAG CGG ATG ACA ACA (F) and 5'-TCA GCT GAG CAG CCA CAG CAG (R); cav-1 : 5'-ATG TCT GGG GGC AAA TAC GTA GAC TCG GAG (F) and 5'-TTA TAT TTC TTT CTG CAA GTT GAT GCG GAC (R); b-actin: 5'-CAT CGT GGG CCG CTC TAG GCA (F) and 5'-CCG GCC AGC CAA GTC CAG ACG (R). A quarter of each ampli®cation product was run on a 1% agarose gel and 0.5 mg of Hae-digested FX was used as size marker.
Vector construction and transfection
The human aFR cDNA cloned into the pcDNAI/neo vector was used to transfect NIH3T3 cells (Bottero et al., 1993) , L-SKOV3 and A431 cells. Full-length human caveolin cDNA was derived from A431 cell total RNA, using the primers above. After complete sequencing, the cDNA was cloned into the pCR3.1-Uni vector using the Eukaryotic TA Cloning kit (unidirectional) essentially as described by the manufacturer (Invitrogen, San Diego, CA, USA and used to transfect L-IGROV1 cells. cells/well) in 96-well plates in their respective medium plus 10% FCS, and incubated at 378C for 24 h; the following day, cells (about 40% con¯uent) were washed, incubated for 4 h in medium without FCS. Vector (15 mg) containing either human aFR, or cav-1 cDNA, or the vector alone (mock) plus 20 mg of lipofectin diluted in 0.9% NaCl, was added. After 24 h, the medium was replaced and 10% FCS was added. After an additional 24 h, G418 was added to the growth medium at a ®nal concentration of 800 mg/ml (aFR-and mocktransfected cells) or 400 mg/ml (cav-1-and mock-transfected cells). Surviving clones were tested for aFR or cav-1 expression.
Electron microscopy
For ultrastructural evaluation of caveolar structures, cells were ®xed in 2% glutaraldehyde in PBS for 2 h at 48C and post-®xed in 1% osmium tetroxide in Veronal acetate buer, pH 7.4, for 2 h at 48C. Samples were stained with 1% uranyl acetate, dehydrated in acetone and embedded in Epon 812. Ultrathin sections were post-stained with uranyl acetate and lead citrate and examined under a Philips CM100 electron microscope (Eindhoven, Netherlands).
A modi®cation of a pre-embedding technique (Smart et al., 1994) was used for immunodetection of cav-1. Brie¯y, both mock-and cav-1-transfected cells were washed quickly with PBS and ®xed with 3% (w/v) paraformaldehyde for 45 min at room temperature. After a 10 min rinse in PBS, cells were incubated with 100 mM NH 4 Cl for 10 min at 48C, rinsed in PBS, and treated with 0.15% BSA plus 0.01% saponin in PBS for 30 min at 48C. Samples were incubated with rabbit anti-cav-1 polyclonal antibody, rinsed and incubated with goat anti-rabbit IgG conjugated with 10 nm gold beads (Sigma). Both incubations were for 1 h at 48C with antibodies dissolved in PBS plus 0.15% BSA and 0.01% saponin. Cells were ®xed in 2% glutaraldehyde and processed as described above for eponate embedding.
Proliferation assays
For in vitro growth, mock-and cav-1-transfected cells were seeded at 5610 4 /well in triplicate, in 6-well plates. Proliferation was evaluated every 2 days by cell counting based on Trypan Blue exclusion.
For foci formation assay: mock-transfected IGt-M87 and cav-1-transfected IGt-C3 cells were seeded at a density of 2500 per 10 mm petri plates, and continuously grown for 15 days in their appropriate medium. Plates were stained using the Di Quick Staining kit (Baxter Dade; Dudingen, Switzerland) essentially as described by the manufacturer. The number of foci within a homogeneous central area of the plate was evaluated. Alternatively, cells were trypsinized and counted by Trypan Blue exclusion.
For soft agar growth, 1610 4 cells were plated in triplicate in 6-well plates in 0.33% soft-agarose layered on 1% agarose and continuously grown for 20 days.
Transient transfection and CAT assay
The P1PD-CAT, P4HA-CAT (Elwood et al., 1997) and the P1PCR4-CAT constructs were used for transient transfection assays; P1PCR4 was ampli®ed from P1PD using the following oligonucletides: F: 5'-GGATCCAAGCTTCGCC-CAATCCCAGGCTCCA and R: 5'-AGGAGGTCTAGAG-GAATGCCATAGGGTGTGT.
These oligonucleotides included the restriction sites HindIII at the 5'-end and XbaI at the 3'-end for cloning of the PCR product into the multiple cloning site of pCAT basic.
Cav-1-transfected and mock-transfected IGROV1 cells (4610 5 ) were seeded in 6-well plates in the appropriate culture medium. The following day, cells (40 ± 50% con¯uent) were washed and 3 ml of RPMI without FCS was added to each well. After 4 h, CAT constructs (2.5 mg/well) were cotransfected by using the lipofectin technique with 0.02 mg CMV-Luc, containing the luciferase gene downstream of a CMV promoter, as a control for transfection eciency. Fluorescence intensity was evaluated using a TD Luminometer (Promega). CAT activity was evaluated as described (Saikawa et al., 1995) in cell lysates normalized for transfection eciency and the extent of chloramphenicol acetylation was determined by PhosphoImager Imagequant software.
Gel shift assay (GSA)
Nuclear extracts (NE) were prepared essentially as described (Saikawa et al., 1995) in the presence of phosphatase inhibitors (Phosphatase Inhibitors Cocktail I and II, SIGMA) using 8610 7 IGt-M87 or IGt-C3 cells as starting material. Protein concentration was determined by the BCA assay and samples were frozen in dry ice and stored at 7808C. Probes were prepared by PCR ampli®cation, using P1PD-CAT construct as template and the following primers: Probe A: 5'-TGG CCT TCG CCC AAT CCC AGG CT (F), 5'-CCC CCT TGC CTT ATT CC (R); Probe B: 5'-GGA ATA AGG CAA GGG GG (F), 5'-GGG AAT GCC ATA GGG TGT GTG (R). DNA (300 ng) was labeled with a 5' polynucleotide kinase (10 U, Biolab) and 30 mCi of [g-32 P]ATP. Material corresponding to 200 000 c.p.m. was incubated for 30 min at room temperature with 5 mg of NE, and 100 mg/ml poly(dl)-(dC) (Pharmacia) in GSA buer (10 mM Tris-HCl, 50 mM NaCl, 0.5 mM DTT, 10% glycerol, 0.05% NP40 and phosphatase inhibitors as above), with or without a 50-fold excess of speci®c probe as competitor. Samples were resolved in a 5% native polyacrylamide gel. The gel was dried and exposed to PhosphoImager.
